<DOC>
	<DOCNO>NCT03042793</DOCNO>
	<brief_summary>Title : Vaccination PD-L1 peptide Montanide multiple myeloma high dose chemotherapy stem cell support . A phase I first-in-human study . Hypothesis : In trial investigator assess new immunotherapeutic strategy target immune checkpoint molecule PD-L1 investigate potential vaccination PD-L1 possible anticancer target .</brief_summary>
	<brief_title>Vaccination With PD-L1 Peptide Against Multiple Myeloma</brief_title>
	<detailed_description>Background : Multiple myeloma second common hematologic cancer despite advance treatment still incurable patient . In trial investigator assess new immunotherapeutic strategy target immune checkpoint molecule PD-L1 investigate potential vaccination PD-L1 possible anticancer target . PD-L1 recognize important factor immune regulation development immune tolerance microenvironment cancer cell . Cells express PD-L1 surface know inhibit immune system . As see recent advance immunotherapy cancer antibody PD-L1 , immunosuppressive role molecule PD-L1 antagonized benefit patient cancer . PD-L1 express cancer cell , antigen present cell immunosuppressive cell tumor micro-environment . Vaccination PD-L1 therefore two side . The investigator aim stimulate PD-L1 specific T-cells , hence eliminate PD-L1 positive tumor cell well PD-L1 positive immunosuppressive antigen present cell tumor microenvironment . The primary endpoint safety toxicity evaluation . Secondary endpoint immunological response . Clinical response described .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Histologically verified multiple myeloma 2 . Newly treat HDT sign relapse 3 . Age ≥18 year 4 . Performance status ≤ 2 ( ECOGscale ) 5 . Expected survival &gt; 3 month 6 . Sufficiently regenerate bone marrow function , i.e . 1 . Leucocytes ≥ 1,5 x 109 2 . Granulocytes ≥ 1,0 x 109 3 . Thrombocytes ≥ 20 x 109 7 . Creatinine &lt; 2.5 upper normal limit , i.e . &lt; 300 μmol/l 8 . Sufficient liver function , i.e . 1 . ALAT &lt; 2.5 upper normal limit , i.e . ALAT &lt; 112 U/l 2 . Bilirubin &lt; 30 U/l 9 . Women agreement use contraceptive method failure rate &lt; 1 % per year treatment period least 120 day last treatment . 10 . For men : agreement use contraceptive measure agreement refrain donate sperm . 1 . Nonsecretory myeloma 2 . Other malignancy medical history exclude squamous cell carcinoma skin patient cure another malignant disease sign relapse three year end treatment . 3 . Significant medical condition per investigator judgement e.g . severe Asthma/COPD , poorly regulate heart condition , insulin dependent diabetes mellitus . 4 . Acute chronic viral infection e.g . HIV , hepatitis tuberculosis 5 . Serious known allergy earlier anaphylactic reaction . 6 . Known sensibility towards Montanide ISA51 7 . Any active autoimmune disease e.g . autoimmune neutropenia , thrombocytopenia hemolytic anemia , systemic lupus erythematosus , scleroderma , myasthenia gravis , autoimmune glomerulonephritis , autoimmune adrenal deficiency , autoimmune thyroiditis etc . 8 . Pregnant breastfeed woman . 9 . Fertile woman use secure contraception failure rate less &lt; 1 % 10 . Patients take immune suppressive medication incl . corticosteroid methotrexate time enrollment 11 . Psychiatric disorder per investigator judgment could influence compliance . 12 . Treatment experimental drug 13 . Treatment anticancer drug except bisphosphonates denosumab 14 . Patients active uncontrolled hypercalcemia 15 . Patients receive chemotherapy , immune therapy , radiation therapy within last 28 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>myeloma</keyword>
	<keyword>vaccination</keyword>
	<keyword>PD-L1</keyword>
	<keyword>peptide vaccine</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>immunotherapy</keyword>
</DOC>